Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Defense & Aerospace

L3Harris Shares Gain Momentum with Major Korean Defense Contract

Robert Sasse by Robert Sasse
November 3, 2025
in Defense & Aerospace, Earnings, Mergers & Acquisitions
0
L3Harris Stock
0
SHARES
10
VIEWS
Share on FacebookShare on Twitter

Defense contractor L3Harris Technologies is demonstrating strong operational performance, exceeding market expectations while securing a substantial international agreement with South Korea. The company’s latest quarterly results have generated positive sentiment among investors, with the newly announced multi-billion dollar deal potentially providing additional upward pressure on the stock.

Strategic International Contract Strengthens Position

In a significant development following the quarter’s end, L3Harris announced a landmark $2.2 billion agreement with South Korea for Airborne Early Warning and Control aircraft systems. This substantial international award highlights increasing global demand for the company’s defense technology solutions.

Chief Executive Officer Christopher Kubasik emphasized the strategic importance of this partnership, which involves collaboration with industry partners including Bombardier and Israel Aerospace Industries. The project not only reinforces L3Harris’s market standing but also creates opportunities for additional international business amid current geopolitical tensions.

Quarterly Performance Exceeds Projections

For the third quarter of 2025, L3Harris reported unexpectedly robust financial results. Earnings per share reached $2.70, comfortably surpassing analyst projections of $2.60. The company posted equally impressive revenue growth, with sales advancing 6.9% to $5.66 billion, exceeding market forecasts.

Perhaps most notably, organic growth registered at ten percent, indicating strong underlying business performance. This positive trajectory prompted management to upwardly revise full-year guidance. For 2025, L3Harris now anticipates revenue of $22 billion with earnings per share projected between $10.50 and $10.70.

Should investors sell immediately? Or is it worth buying L3Harris?

The company’s order intake totaled $6.7 billion, resulting in a healthy book-to-bill ratio of 1.2, suggesting continued demand momentum.

Operational Efficiency and Future Outlook

L3Harris has now achieved operational margin expansion for eight consecutive quarters, demonstrating successful cost management initiatives and improving efficiency. Despite temporary payment delays on some government contracts, the company maintains its free cash flow projection of $2.65 billion.

Strategic acquisitions, particularly Aerojet Rocketdyne, continue to deliver value and contribute meaningfully to growth. Since the acquisition, solid rocket motor deliveries have surged by more than 400 percent. Management expressed confidence in achieving its financial targets for 2026.

With the foundation for sustained growth apparently established, market observers now await execution on these promising developments across future quarters.

Ad

L3Harris Stock: Buy or Sell?! New L3Harris Analysis from February 7 delivers the answer:

The latest L3Harris figures speak for themselves: Urgent action needed for L3Harris investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

L3Harris: Buy or sell? Read more here...

Tags: L3Harris
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Universal Insurance Stock
Analysis

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

February 7, 2026
Embecta Stock
Earnings

Embecta’s Q1 Performance Outpaces Analyst Forecasts

February 7, 2026
Camping World Stock
Consumer & Luxury

Camping World’s New Leadership Faces First Major Test

February 7, 2026
Next Post
Denali Therapeutics Stock

Denali Therapeutics Faces Critical Investor Update Amid Regulatory Setback

Qualcomm Stock

Qualcomm's Strategic Pivot: Challenging AI Dominance with Billion-Dollar Deal

Iovance Stock

Iovance Shares Surge on Groundbreaking Lung Cancer Trial Results

Recommended

CRWD stock news

Tower Research Capital LLC TRC Demonstrates Unwavering Confidence in CrowdStrike Holdings as Cybersecurity Leader

2 years ago
Efficiently Reporting an Absence on WalmartOne: A Step-by-Step Guide for Employees

Beacon Announces Interim Chief Financial Officer

2 years ago

Alaska Airlines Boeing 737 Investigation Missing Bolts and Safety Measures

2 years ago

Impressive Financial Performance for Kiniksa Pharmaceuticals

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

Diginex Enters Critical Implementation Phase Following Strategic Moves

Deluxe Stock Gains Momentum on Successful Fintech Transition

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

Trending

Universal Insurance Stock
Analysis

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

by Rodolfo Hanigan
February 7, 2026
0

Universal Insurance Holdings has reaffirmed its commitment to shareholder returns, declaring its regular quarterly dividend despite a...

Embecta Stock

Embecta’s Q1 Performance Outpaces Analyst Forecasts

February 7, 2026
Camping World Stock

Camping World’s New Leadership Faces First Major Test

February 7, 2026
Viking Therapeutics Stock

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

February 7, 2026
Diginex Stock

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds
  • Embecta’s Q1 Performance Outpaces Analyst Forecasts
  • Camping World’s New Leadership Faces First Major Test

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com